Drug Trial Radar · NCT05609370
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
113
Actual
Start
Jan 29, 2023
Primary completion
May 23, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
AlcestobartDrug
Administered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks
TislelizumabDrug
Administered intravenously at a dose of either 200 mg once every 3 weeks or 300 mg once every 4 weeks.
Bevacizumab or Bevacizumab biosimilarDrug
Administered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks.
Fluoropyrimidine (FP)Drug
Fluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.
- Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and CTime frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)
Locations
64 sites in 4 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, Llc
Anchorage, Alaska
Banner Md Anderson Cancer Center
Gilbert, Arizona
Helios Clinical Research
Cerritos, California
Valkyrie Clinical Trials
Los Angeles, California
Usc Norris Comprehensive Cancer Center (Nccc)
Los Angeles, California
UCLA Hematologyoncology
Los Angeles, California
Hoag Memorial Presbyterian
Newport Beach, California
Kaiser Permanente Northern California
Vallejo, California
Baptist Md Anderson Cancer Center
Jacksonville, Florida
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Baptist Health Lexington
Lexington, Kentucky
University of Kentucky Markey Cancer Center
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Pontchartrain Cancer Center
Covington, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
Washington University School of Medicine
St Louis, Missouri
St Vincent Frontier Cancer Center
Billings, Montana
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Cancer Care Specialists
Reno, Nevada
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Perlmutter Cancer Center At Winthrop Oncology Hematology Associatesnyu Winthrop Hospital
Mineola, New York
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health
New York, New York
Columbia University Medical Center
New York, New York
Duke Cancer Center
Durham, North Carolina
University of Tennessee Medical Center
Knoxville, Tennessee
Ut Southwestern Medical Center
Dallas, Texas
Ut Health San Antonio Mays Cancer Center
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Cancer Care Northwest
Spokane Valley, Washington
Multicare Health System Institute For Research and Innovation
Tacoma, Washington
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
Orange Health Service (Central West Cancer Care Centre)
Orange, New South Wales, Australia
Riverina Cancer Care Centre
Wagga Wagga, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
St John of God, Murdoch
Murdoch, Western Australia, Australia
One Clinical Research
Nedlands, Western Australia, Australia
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.